دورية أكاديمية
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.
| العنوان: | Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. |
|---|---|
| المؤلفون: | Jagannath VA; Department of Paediatrics, American Mission Hospital, Manama, Manama, Bahrain, PO Box 1., Asokan GV, Fedorowicz Z, Lee TW |
| المصدر: | The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2016 Feb 24; Vol. 2. Cochrane AN: CD008139. Date of Electronic Publication: 2016 Feb 24. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : Chichester, West Sussex, England : Wiley Original Publication: Oxford, U.K. ; Vista, CA : Update Software, |
| مواضيع طبية MeSH: | Cystic Fibrosis/*complications , Enzyme Inhibitors/*therapeutic use , Influenza, Human/*drug therapy , Neuraminidase/*antagonists & inhibitors, Humans |
| مستخلص: | Background: Cystic fibrosis is the most common, life-threatening, recessively inherited disease of Caucasian populations. It is a multisystem disorder caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein which is important in producing sweat, digestive juices and mucus.The impaired or absent function of this protein results in the production of viscous mucus within the lungs and an environment that is susceptible to chronic airway obstruction and pulmonary colonization by a range of pathogenic bacteria. Morbidity and mortality of cystic fibrosis is related to chronic pulmonary sepsis and its complications by these bacteria.Influenza can worsen the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. Antiviral agents form an important part of influenza management and include the neuraminidase inhibitors zanamivir and oseltamivir. These inhibitors can limit the infection and prevent the spread of the virus. Objectives: To assess the effects of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Search Methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent search: 02 November 2015. Selection Criteria: Randomised controlled trials and quasi-randomised controlled trials comparing neuraminidase inhibitors with placebo or other antiviral drugs. Data Collection and Analysis: Two review authors had planned to independently screen studies, extract data and assess risk of bias using standard Cochrane methodologies. No studies were identified for inclusion. Main Results: No relevant studies were retrieved after a comprehensive search of the literature. Authors' Conclusions: We were unable to identify any randomised controlled studies or quasi-randomised controlled studies on the efficacy of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. The absence of high level evidence for the effectiveness of these interventions emphasises the need for well-designed, adequately powered, randomised controlled clinical studies. |
| التعليقات: | Update of: Cochrane Database Syst Rev. 2014 Feb 10;(2):CD008139. doi: 10.1002/14651858.CD008139.pub3. (PMID: 24515341) |
| References: | Cochrane Database Syst Rev. 2009 Oct 07;(4):CD001753. (PMID: 19821281) Health Technol Assess. 2002;6(9):1-87. (PMID: 12065066) Expert Opin Drug Saf. 2009 May;8(3):357-71. (PMID: 19355841) Lancet. 2003 Feb 22;361(9358):681-9. (PMID: 12606185) Cochrane Database Syst Rev. 2014 Feb 10;(2):CD008139. (PMID: 24515341) Thorax. 1992 Feb;47(2):112-4. (PMID: 1549818) Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001265. (PMID: 16855962) Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008139. (PMID: 20238363) J Virol. 2004 Nov;78(22):12665-7. (PMID: 15507653) PLoS One. 2013;8(4):e60348. (PMID: 23565231) BMJ. 2003 Jun 7;326(7401):1235. (PMID: 12791735) J Cyst Fibros. 2008 Jan;7(1):85-8. (PMID: 17616444) MMWR Recomm Rep. 2008 Aug 8;57(RR-7):1-60. (PMID: 18685555) Pediatrics. 2008 Dec;122(6):1171-6. (PMID: 19047230) Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170. (PMID: 14609480) N Engl J Med. 2005 Sep 29;353(13):1363-73. (PMID: 16192481) Arch Dis Child. 1995 Aug;73(2):117-20. (PMID: 7574853) Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. (PMID: 22258996) Cochrane Database Syst Rev. 2007 Apr 18;(2):CD001269. (PMID: 17443504) J Infect Dis. 2004 Feb 1;189(3):440-9. (PMID: 14745701) Pediatr Pulmonol. 1998 Dec;26(6):371-9. (PMID: 9888211) Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002744. (PMID: 17253479) BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) |
| المشرفين على المادة: | 0 (Enzyme Inhibitors) EC 3.2.1.18 (Neuraminidase) |
| تواريخ الأحداث: | Date Created: 20160225 Date Completed: 20160620 Latest Revision: 20240824 |
| رمز التحديث: | 20240826 |
| مُعرف محوري في PubMed: | PMC7199381 |
| DOI: | 10.1002/14651858.CD008139.pub4 |
| PMID: | 26905631 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1469-493X |
|---|---|
| DOI: | 10.1002/14651858.CD008139.pub4 |